Drug Trial Radar · NCT07514975
First-In-Human Study of KHN922 for Injection
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Apr 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumors Cancer
Interventions
KHN922 for injectionDrug
KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens,intravenous (IV) administration every three weeks (D1) .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Objective Response Rate (ORR)Time frame: up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.